Wire · opportunities
Medtronic expands cSDH treatment options with US FDA clearance of Aristotle Mini guidewire
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 November 2026 · Fusion42 review
Medtronic received US FDA clearance for the Aristotle Mini guidewire, expanding its neurovascular treatment options for chronic subdural haematoma (cSDH) with a low-profile device designed for navigating small, distal brain vessels. The new guidewire complements Medtronic’s existing neurovascular products and is being commercially introduced after their acquisition of Scientia Vascular.
This Wire brief sits within Fusion42's coverage of Medtech, and 3 sources have reported it between 9 Nov 2026 and 15 Nov 2026.
◆ ◆ The Wire takeaway
You can now offer patients more precise treatments for chronic subdural haematoma with a new low-profile guidewire that improves access within tricky brain vessels. If your medtech product mixes navigation and embolic therapy, new competition and standards have emerged.
◆ Coverage
3 sources · first reported 9 Nov 2026 · latest 15 Nov 2026
◆ Related on Wire
◆ Topics